Meet the Combined Company’s Future Leadership Team
Giovanni Caforio, M.D. has been Chief Executive Officer of Bristol-Myers Squibb since May 2015 and has been serving on the company’s Board of Directors since June 2014. In May 2017, he assumed the role of Chairman of the Board.
As CEO, Caforio has led the company’s focus on researching and developing transformational medicines, which includes a leading portfolio of immunotherapies that are fundamentally changing the way cancer is treated. Under his leadership, BMS is evolving its operating model, in order to increase speed and competitiveness.
With a background as a physician, Caforio has helped strengthen the company’s patient-focused culture – one driven by innovation, speed, accountability and passion. As a leader, he is focused on the business value of a company culture that promotes and rewards diversity and inclusion.
Prior to becoming CEO, Caforio served as Chief Operating Officer with responsibility for leading a fully integrated worldwide commercial organization and the companywide functions of Enterprise Services and Global Manufacturing & Supply. This was preceded by his work as the company’s Chief Commercial Officer.
Caforio joined Bristol-Myers Squibb in 2000 as Vice President and General Manager, Italy, in the Worldwide Medicines Group. He assumed added responsibility for Greece and Israel in 2001, and for South East Europe in 2003. In 2004, he was appointed Senior Vice President, European Marketing and Brand Commercialization. In 2007, he relocated to the U.S. to assume the role of Senior Vice President, U.S. Oncology. In 2010, he was named Senior Vice President, Global Commercialization, Oncology and Immunology, before becoming President of the company’s U.S. organization in 2011. Prior to joining Bristol-Myers Squibb, Caforio spent 12 years with Abbott Laboratories in a number of leadership positions.
Born and educated in Italy, Caforio received his M.D. from the University of Rome.
Nadim Ahmed was named President, Global Hematology & Oncology Franchise in August 2017. Previously, he was President of Worldwide Markets for the Hematology & Oncology Franchise. Ahmed served as General Manager, U.S. Hematology & Oncology from August 2014 until March 2016. He joined Celgene in 2010 as Global Head of Marketing for Celgene’s Multiple Myeloma Franchise after holding positions of increasing responsibility in Clinical Development, Medical Affairs, Global and U.S. Marketing at GlaxoSmithKline. Ahmed has over 25 years of industry experience.
Ahmed holds a B.S. degree in Pharmacology from University College London, UK and an M.S. in Information Technology from Loughborough University, UK. He serves on the Board of Directors of Family Promise, a not-for-profit organization helping homeless families.
As the company’s Chief Financial Officer and Head of Global Business Operations, Charles Bancroft oversees Global Finance, Business Insights & Analytics, Global Procurement and Information Technology. These integrated functions bring a combination of bold, consultative expertise and operational excellence that drives and sustains business success. They strive to continuously improve performance and efficiency, while delivering strategic guidance that empowers and accelerates critical decisions across the company.
“I have tremendous pride in being part of a company where everyone, in every role, is deeply focused on patients. We are committed to our Mission, which you can see in our investment choices, our culture and our science,” said Bancroft.
Bancroft joined the company in 1984, coming from KPMG. During the ensuing years, he has held positions of increasing responsibility within the finance organization, including international assignments, and has had commercial operational responsibility for Latin American, Middle East, Africa, Canada, Japan and several Pacific Rim countries. He was first named Chief Financial Officer in 2010.
Bancroft received his Bachelor of Science degree in accounting from Drexel University and his Masters in Business Administration from Temple University. He is a member of the Board of Directors of Colgate-Palmolive Company.
Paul Biondi is Senior Vice President, Head of Strategy and Business Development. He has enterprise-wide responsibility for establishing and evolving the company strategy, and leading the pursuit of strategic transactions that provide access to external innovation, enhance company capabilities and evolve the portfolio over time. Biondi also has accountability for maintaining the company’s focus on continuous improvement and prioritization of resources.
Biondi was appointed Head of Business Development in 2015, and under his leadership, Bristol-Myers Squibb expanded its range of deal-making efforts to partner valuable science, research and technology together with its pipeline and capabilities to help execute the company strategy, deliver growth and diversify the portfolio.
“Bristol-Myers Squibb has a differentiated strategy to bring transformational medicines to patients in need,” said Biondi. “We are committed to ensuring we stay at the forefront of therapeutic innovation through the continuous refinement of our strategic focus, capabilities and execution.”
Prior to being appointed Head of Business Development, Biondi worked in Bristol-Myers Squibb’s R&D Operations for 10 years where he held positions of increasing responsibility providing strategic insights and operations excellence to enhance the performance of the R&D organization. As head of R&D Operations, he was responsible for optimizing the delivery of the pipeline, managing the portfolio and delivering early- and late-stage clinical operations. In this role, Biondi worked closely with the Business Development leaders in formulating portfolio strategies as well as overseeing integrations of scientific assets or acquired companies.
Biondi joined Bristol-Myers Squibb in 2002 and holds a bachelor’s degree in government and economics from Dartmouth College and an M.B.A. from J.L. Kellogg School of Management at Northwestern University.
Christopher Boerner is Chief Commercial Officer of Bristol-Myers Squibb, where he leads commercial strategy and execution across all geographies. In his previous role, Boerner was head of international markets at Bristol-Myers Squibb, accountable for commercial activities in all ex-U.S. markets. He joined the company in February 2015.
“I look forward to continuing to help BMS deliver on our mission of bringing transformational medicines to patients,” Boerner said. “By focusing on innovation and execution, we can strengthen our ability to bring innovative medicines to patients faster.”
Prior to joining Bristol-Myers Squibb, Boerner served as the Executive Vice President of Commercial for Seattle Genetics, Inc., where he led all commercial activities for the company, as well as Senior Vice President of Commercial and Vice President of Marketing.
Before joining Seattle Genetics, Boerner worked for Dendreon Corporation, where he led the marketing team. From 2002 to 2010, he worked for Genentech, a member of the Roche Group, where he served in a variety of commercial roles, including Director of Marketing on Avastin. Prior to Genentech, he worked for McKinsey & Company, serving global pharmaceutical and biotechnology clients.
Boerner received his Ph.D. and M.A. in Business Administration from the Haas School of Business at the University of California, Berkeley, and holds an A.B. in economics and history from Washington University in St. Louis.
As Chief Compliance and Ethics Officer, Adam Dubow leads the company’s efforts to ensure its operations are conducted in compliance with ethical business practices, its Principles of Integrity, as well as laws and regulations in the markets it operates. In addition to reporting to the General Counsel and CEO, Dubow also reports to the Chair of the Audit Committee of the Board of Directors.
“Our focus on ethics and integrity is critical to the success of our company,” says Dubow. “Ensuring we maintain an unwavering focus on the highest standards will help ensure we meet the commitments we have made to our patients, employees, communities where we work and our shareholders.”
Dubow most recently served as Vice President and Associate General Counsel supporting the R&D organization. Prior to that Dubow provided strategic counsel to the company’s Leadership Team on policy issues and represented the company externally as the Lead of Global and Corporate Policy.
Dubow joined Bristol-Myers Squibb in 1999 and has held a diverse set of roles with progressively increasing responsibility within the Law Department. As counsel for the U.S. Pharmaceuticals business, Dubow advised the Oncology, Virology and Immunoscience business units on regulatory, compliance, contractual and commercial matters. He also had international roles in Singapore and Paris, France where he led law departments for the company’s Asia Pacific and Japan and the Europe, Middle East and Africa regions. Prior to joining Bristol-Myers Squibb, Dubow was a Partner at the law firm of Sedgwick, Detert, Moran and Arnold in New York.
Dubow holds a B.A. in Psychology from Brandeis University and a J.D. from Fordham University.
Joseph E. Eid, MD, has been Senior Vice President and Head of Global Medical Affairs for Bristol-Myers Squibb since November 13, 2017. He is a member of the Leadership Team of BMS.
Before joining BMS in 2017, he spent 9 years at Merck & Co., Inc., most recently as a Vice President and Head of Oncology Global Medical Affairs, overseeing all worldwide oncology medical functions and activities. Before assuming his role in Oncology Medical Affairs, Eid served in Merck Research Labs as the team leader for Pembrolizumab (anti-PD-1 antibody), where he managed the first in man trials and set the strategy that lead to the first FDA anti-PD-1 antibody approval. Prior to Merck & Co., Inc., he was Clinical Team Leader, and Science Team Leader at Hoffmann-La Roche AG in Oncology Clinical Research.
Eid holds a medical degree from St. Joseph University School of Medicine in Beirut, Lebanon. He completed his fellowship in hematology and medical oncology at Rutgers-Robert Wood Johnson Medical School (RWJMS) and was appointed to the faculty at RWJMS as Assistant Professor of Medicine in the Departments of Medicine and Pathology and Laboratory Medicine. Eid is a licensed physician in New Jersey.
John Elicker is senior vice president, Corporate Affairs and Investor Relations. In this role, Elicker leads Bristol-Myers Squibb’s internal and external communications efforts worldwide, which includes responsibility for Global Policy, Advocacy and Government Affairs as well as the company’s interactions with the investment community.
Under Elicker’s leadership, the company has built one of the best investor relations teams in the industry as named by investors polled by Institutional Investor magazine. In addition, he has aligned the communications organization around the company’s core business objectives and accelerated the development and launch of the company’s social media platforms.
“We have an important story to tell about Bristol-Myers Squibb and our focus on transforming the way diseases are treated, our differentiated approach to business, the scientific expertise of our researchers and the passion our employees bring to helping patients,” said Elicker.
Elicker joined Bristol-Myers Squibb in 2000 as Senior Director, Investor Relations. In 2002, he became Vice President, Investor Relations, and the company’s primary contact with the institutional investment community. In 2011, Elicker added responsibility for Public Affairs, and in 2017 assumed leadership for Global Policy, Advocacy and Government Affairs.
Prior to joining Bristol-Myers Squibb, Elicker held various leadership roles of increasing responsibility at W. W. Grainger, Inc. and at Scott Paper Company.
Elicker received a Bachelor of Science degree from Pennsylvania State University and holds a Masters of Business Administration degree from The Wharton School at the University of Pennsylvania.
David Elkins joined Celgene in July 2018. He came to Celgene from Johnson & Johnson (J&J), where he was Worldwide Vice President and Chief Financial Officer for Consumer Products, Medical Devices and Corporate Functions. Prior to J&J, Elkins was CFO for Round Rock Research, a technology investigation and patent licensing company. From 2008 to 2012, Elkins was Executive Vice President and CFO of Becton, Dickinson and Company, a public global medical technology company. From 1995 to 2008, he held roles of increasing responsibility at AstraZeneca, and he began his career in finance at the Boeing Company in 1991.
Elkins holds a B.S. degree from the University of Delaware, an M.S. from the University of Pennsylvania and an M.B.A. from Drexel University.
Samit Hirawat, M.D., will join BMS from Novartis, where he most recently served as Executive Vice President and Head of Oncology Global Development.
Hirawat is a highly collaborative leader who brings extensive drug development experience to the role. Prior to Novartis, Hirawat led clinical development programs in multiple indications at PTC Therapeutics and Pfizer/Pharmacia Corporation.
Hirawat received his Bachelor of Medicine and Bachelor of Surgery (M.B; B.S.) from the Sawai Man Singh Medical College in India, and completed his Internal Medicine Residency and Medical Oncology Training at North Shore University Hospital, New York. He is an author of several manuscripts and abstracts published in peer reviewed journals and presented at major conferences. Hirawat is a recipient of several government grants, academic and corporate awards.
Severine LaCourt joined Bristol-Myers Squibb nine years ago. Based in Princeton for the past three years, she most recently was leading the worldwide Biomarkers commercialization group while being in charge of the commercial Cell Therapy integration team, and prior to this role, was leading the worldwide commercial Hematology team.
LaCourt has spent three years in BMS China as the Head of Commercial Excellence and then Product and Portfolio Strategy. Prior roles include BUD Virology in France and Amylin European Integration Lead.
After starting her career with The Boston Consulting Group, LaCourt joined the Pharma Industry and now has 20 years of experience in strategy, marketing, sales, BU management and strategic project management, across diverse therapeutic areas (CNS, CV, Diabetes, HIV, Hepatitis, Hematology & Immuno-Oncology), in diverse settings (National, European, Global) in Europe, China and the U.S. With a broad knowledge of health models (BioPharma, medical device and pharmaceuticals), she has consistently led by developing vision and strategic thinking, with an ability to challenge the status quo and energize and develop the team, while relentlessly delivering on results. LaCourt has led two turnarounds, led across three alliance partnerships (BMS / sanofi; BMS / AZ, BMS/Gilead), and successfully launched new products and indications (Plavix, Empliciti).
She has been the B-NOW Market Place lead in 2017, contributing to creating opportunities for women to increase their visibility through innovative business projects.
LaCourt has a degree in Business & Entrepreneurship from HEC School of Management, an MBA degree from INSEAD. She lives with her husband and two teenagers in New York, and enjoys practicing yoga and skiing.
Sandy Leung serves as legal advisor to the Board of Directors and company executives, and is responsible for shaping the company’s legal strategy. Leung is also responsible for Environment, Health & Safety & Sustainability, Corporate Security and Philanthropy.
“The accelerating pace of science, governmental policies and regulations and overall global complexity across our industry requires us to be even more agile than ever,” says Leung. “Our legal team brings strategic value across all aspects of our business through practical and sound counsel that guide our company in its mission to help patients.”
Leung joined Bristol-Myers Squibb in 1992 as a staff attorney in the litigation department. In 1996, she became Assistant Counsel and one year later, was named Associate Counsel. In 1999, Sandy was appointed to the position of Counsel and Corporate Secretary. In 2006, she was appointed Acting General Counsel and in 2007, she was named General Counsel. In 2014, Sandy was named Executive Vice President.
Prior to joining the company, Leung was a prosecutor in the Manhattan District Attorney’s Office.
“My advice to those aspiring to management positions is to be good at what you do. You have to be willing to do the hard work and bring good excellent judgment and expertise to the table. Most important, you must have great personal integrity and be someone people can trust. If people trust you, they will feel comfortable seeking your advice. Also, be respectful of people, not just your superiors but everyone.”
Leung earned her law degree from Boston College of Law and her bachelor’s degree from Tufts University.
Ann Powell Judge is the Global Head of Human Resources with direct responsibility for driving the corporation’s global capabilities in talent management, culture and organizational effectiveness tied directly to business performance.
Powell works across the enterprise to support Bristol-Myers Squibb’s commitment to creating an energizing work experience and a culture that is powerfully diverse and broadly inclusive, where individuals are encouraged to exceed their potential and inspired to make innovative contributions for our patients and the global communities in which they live and work.
“The courage and passion of our workforce is truly inspiring and drives an even higher level of engagement in making a difference in the lives of patients,” said Powell.
Powell’s industry experience and expertise lie in executive compensation, leadership development, change management, diversity/inclusion, training design and delivery, talent acquisition, labor relations, mergers and acquisitions, divestitures and start-ups.
With a career spanning both international and domestic assignments, Powell has held leadership roles of increasing responsibility within both the chemical and pharmaceutical industries, including Dow Chemical and Wyeth Pharmaceuticals. Prior to joining Bristol-Myers Squibb in 2013, Powell was the Chief Human Resources Officer for Shire Pharmaceuticals.
Powell earned a Bachelor’s degree from Iowa State University and a Master’s degree in Industrial Relations from the University of Minnesota.
As Senior Vice President and President of Global Product Development and Supply (GPS), Lou Schmukler oversees worldwide product development and manufacturing for Bristol-Myers Squibb. GPS develops and produces active ingredients and drug products, and delivers the company’s medicines throughout the world. The GPS team achieves this mission through a relentless focus on innovation, quality, safety and agility.
“In GPS, we turn molecules into life-changing medicines,” said Schmukler. “Everyone in the organization is dedicated to deliver them in the right way, at the right time, every time for the patients we serve.”
Schmukler joined BMS in 2011 as President of Technical Operations. Prior to joining BMS, he led Pfizer’s worldwide biotech manufacturing operations as Senior Vice President of the Specialty-Biotechnology Operating Unit. Previously, he was responsible for global pharmaceutical manufacturing for Wyeth and Vice President of Quality for Hoffman-LaRoche. Earlier in his career, he also held leadership roles at Marion Merrell Dow, Mallinckrodt and Novartis-Sandoz.
Schmukler is an active member and has held leadership positions in several industry organizations including the Pharmaceutical Research and Manufacturers of America (PhRMA), International Society of Pharmaceutical Engineering (ISPE) and National Association of Manufacturers (NAM).
He holds a Bachelor’s degree in pharmacy from Temple University and a Master’s in management from Webster University.
Rupert Vessey will join BMS from Celgene, where he served as President, Research & Early Development. Prior to joining Celgene in 2015, Vessey spent 10 years at Merck, most recently as Senior Vice President of Early Development and Discovery Sciences.
During his tenure with Merck, Vessey was responsible for numerous drug development programs and served as Senior Vice President, Early Development and Discovery Sciences, Senior Vice President, Respiratory and Immunology Franchise and Vice President, Drug Discovery and Informatics. Prior to Merck, he spent five years at GlaxoSmithKline in drug discovery, experimental medicine and early clinical development of therapeutics for respiratory and immune diseases.
Vessey graduated from Oxford University with degrees in Physiological Sciences (M.A.), Clinical Medicine (B.M., B.Ch.) and a Doctor of Philosophy (D.Phil.) in Molecular Immunology. He is an elected Fellow of the Royal College of Physicians.
Paul von Autenried heads Bristol-Myers Squibb’s Information Technology organization, positioning the company for success in the rapidly evolving digital age. He is focused on ensuring the company’s information assets and operations are reliable, accessible and secure, driving the digitization of the company, adopting new approaches to digital health and continuing an innovative approach to long-term partnerships with key IT service delivery companies.
“It’s an exciting time to lead an IT team as advances in technology are providing new opportunities to streamline our lives in unprecedented ways, including managing our health,” von Autenried said. “Delivering digital capabilities that accelerate the company’s work of bringing innovative medicines to patients is both a challenge and an honor.”
Throughout his experiences in domestic and international high-tech, consumer packaged goods and biopharmaceuticals companies, von Autenried’s career has been focused on strategically leveraging information technology to drive superior performance. Before joining Bristol-Myers Squibb, von Autenried held positions with Kraft General Foods, Hewlett-Packard and IBM. He is a member of the Research Board, and serves on the Board of Trustees of the Princeton Healthcare System.
von Autenried has a Bachelor’s degree in electrical engineering and a Master’s degree in computer science from Stevens Institute of Technology, and has completed the Program for Management Development at Harvard Business School and the Program for Leadership Development at IMD in Switzerland.
*Adam Dubow will continue to report to Sandra Leung, Executive Vice President & General Counsel
**Joseph Eid will report to Chris Boerner, Executive Vice President & Chief Commercialization Officer